Algerian Pharmaceutical Firm Signs Partnership with Chinese Company

Pharma Invest SPA, an Algerian pharmaceutical company, has signed a partnership agreement with China's Yangtze River Pharmaceutical Group. The agreement was signed at the Ministry of Pharmaceutical Industry in Algiers, Algeria, on October 11, 2023. The ceremony was attended by the Minister of Pharmaceutical Industry, Dr. Wissam Qouideri, and officials from the ministry and the public company Sidal.

The partnership aims to enhance cooperation in transferring expertise and modern technologies to control the production of raw materials for pharmaceuticals. It also includes support for Pharma Invest in developing and producing innovative medicines. This will bolster Algeria's technological and industrial capabilities and improve the quality of local production.

During the meeting, preliminary outlines were discussed for a potential upcoming agreement between the public company Sidal and Pharma Invest. This agreement would focus on the production and distribution of high-value-added medicines. The Minister of Pharmaceutical Industry highlighted the importance of such initiatives in guiding the national pharmaceutical industry towards producing innovative medicines and controlling advanced technologies for producing raw materials. This will enhance national capabilities in this field and support the path to achieving health sovereignty.

CONTEXT: This partnership is significant as it represents a strategic move by Algeria to strengthen its pharmaceutical industry through international collaboration. By leveraging Chinese expertise and technology, Algeria aims to enhance its domestic production capabilities and reduce dependence on imports. This initiative aligns with broader goals of achieving self-sufficiency in healthcare and improving the quality of pharmaceutical products available to the Algerian population.